Company
Who We Are
Eve Diagnostics
Eve Diagnostics is the health and wellness arm of Eve Technologies and our key strength lies in providing the most comprehensive and regulated biomarker panel available in the world. Eve Diagnostics is one of only a few laboratories in North America that is regulated for cytokine tests and we are the only laboratory that has been granted large-panel regulation under the Clinical Laboratory Improvement Amendments (CLIA).
Eve Technologies is certified by the Centers for Medicare & Medicaid Services (CMS) as a High Complexity International Laboratory under the CLIA, as defined in U.S. Code of Federal Regulations, Title 42, Chapter IV, Part 493, Laboratory Requirements (42CFR493) 2011 (CLIA# 99D2283230).
We offer Laboratory Developed Tests (LDT) under the speciality Diagnostic Immunology, subspeciality General Immunology. With a test categorization of nonwaived and high complexity testing, this increased complexity parallels increased requirements under CLIA. These assays are not subject to U.S. Food and Drug Administration (FDA) clearance or approval as these tests do not appear on the lists of tests in the Federal Register and the platforms used in specimen analysis have not been reviewed by the U.S. FDA as they are classified as 510(k) exempt.
Clinicians: Check with your State Agency to see if additional Licensure/Registration requirements may apply.
Focus
What We Specialize In
Large-Scale Biomarker Panels, Powered by Advanced Analytics
We specialize in the design, analysis, and interpretation of large biomarker panels—unlocking insights that single-analyte tests cannot provide. By combining high-dimensional laboratory data with modern machine learning approaches, we deliver clinically meaningful results from complex biological signals.
High-Dimensional Testing, Made Actionable
Traditional testing focuses on individual markers. Our approach integrates dozens of biomarkers into a unified analytical framework, capturing patterns, interactions, and subtle shifts that are often missed in isolation.
Built for Real-World Clinical Use
Our testing and analytics pipelines are developed with clinical deployment in mind—ensuring reproducibility, scalability, and clear result interpretation for providers. From data processing and quality control to final reporting, every step is engineered for reliability.
Continuous Optimization
As new data becomes available, our models evolve. We continuously refine biomarker panels and algorithms to improve diagnostic accuracy, adapt to new populations, and incorporate emerging scientific insights.
Our research
Eve Diagnostics is steadfast in its commitment to advancing knowledge and expertise in healthcare science and Clinical Diagnostics. Our ongoing research endeavors aim to enhance our comprehension of the immune environments associated with clinical manifestations in patients with inflammatory, autoimmune, and neoplastic diseases. This, in turn, facilitates more accurate diagnoses and the identification of evidence-based treatment targets. In our publication (Polley et al. Front Immunol 2023), we detail common patterns of immune activation in co-expressing cytokines and their preliminary associations with specific diseases and disease categories.
Eve Diagnostics now offers an even larger, expanded, Comprehensive Cytokine, Chemokine, Growth-Factor 95-Plex Panel. This panel builds on the methodology of our previous research and includes updated cytokine clustering and immune signatures to further enhance the interpretation of results.
For detailed results interpretations, click here.